Home > Medicine > Other > Volume-5 > Issue-4 > Confirmation of Safety of COVID-19 mRNA Vaccination for Cancer Patients

Confirmation of Safety of COVID-19 mRNA Vaccination for Cancer Patients

Call for Papers

Volume-8 | Issue-3

Last date : 26-Jun-2024

Best International Journal
Open Access | Peer Reviewed | Best International Journal | Indexing & IF | 24*7 Support | Dedicated Qualified Team | Rapid Publication Process | International Editor, Reviewer Board | Attractive User Interface with Easy Navigation

Journal Type : Open Access

First Update : Within 7 Days after submittion

Submit Paper Online

For Author

Research Area


Confirmation of Safety of COVID-19 mRNA Vaccination for Cancer Patients


Takuma Hayashi | Nobuo Yaegashi | Ikuo Konishi



Takuma Hayashi | Nobuo Yaegashi | Ikuo Konishi "Confirmation of Safety of COVID-19 mRNA Vaccination for Cancer Patients" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-4, June 2021, pp.1228-1230, URL: https://www.ijtsrd.com/papers/ijtsrd42563.pdf

Patients in the active phase of treatment for cancer are a population at risk of coronavirus disease-19 (COVID-19) with poor prognosis. While a majority of patients treated for cancer expressed their will to be vaccinated as early as December 2020 in a French survey, no data were available in terms of vaccine efficacy and tolerance, because they were excluded from initial registration trials. Several clinical facilities aimed to assess the safety and immunogenicity of the BNT162b2 (Pfizer–BioNTech) vaccine in patients with cancer. In patients with cancer, one dose of the BNT162b2 vaccine yields poor efficacy. Immunogenicity increased significantly in patients with solid cancer within 2 weeks of a vaccine boost at day 21 after the first dose. However, the anti-SARS-CoV-2 immune response was lower in patients with solid tumors who were vaccinated a second dose of BNT162b2 vaccine than in healthy individuals. These data support prioritization of patients with cancer for an early (day 21) second dose of the BNT162b2 vaccine.

COVID-19 mRNAvaccination, COVID-19,SARS-CoV-2,COVID-19 vaccine


IJTSRD42563
Volume-5 | Issue-4, June 2021
1228-1230
IJTSRD | www.ijtsrd.com | E-ISSN 2456-6470
Copyright © 2019 by author(s) and International Journal of Trend in Scientific Research and Development Journal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (http://creativecommons.org/licenses/by/4.0)

International Journal of Trend in Scientific Research and Development - IJTSRD having online ISSN 2456-6470. IJTSRD is a leading Open Access, Peer-Reviewed International Journal which provides rapid publication of your research articles and aims to promote the theory and practice along with knowledge sharing between researchers, developers, engineers, students, and practitioners working in and around the world in many areas like Sciences, Technology, Innovation, Engineering, Agriculture, Management and many more and it is recommended by all Universities, review articles and short communications in all subjects. IJTSRD running an International Journal who are proving quality publication of peer reviewed and refereed international journals from diverse fields that emphasizes new research, development and their applications. IJTSRD provides an online access to exchange your research work, technical notes & surveying results among professionals throughout the world in e-journals. IJTSRD is a fastest growing and dynamic professional organization. The aim of this organization is to provide access not only to world class research resources, but through its professionals aim to bring in a significant transformation in the real of open access journals and online publishing.

Thomson Reuters
Google Scholer
Academia.edu

ResearchBib
Scribd.com
archive

PdfSR
issuu
Slideshare

WorldJournalAlerts
Twitter
Linkedin